San Diego, USA – October 16, 2024
Neuroservices-Alliance and PhenoVista Biosciences are pleased to announce a strategic partnership designed to leverage the complementary strengths of both companies in cell-based assays for CNS drug discovery. This partnership focuses on creating stronger value proposition by combining the expertise in functional electrophysiology from Neuroservices-Alliance and the expertise in creating relevant, complex in vitro models and high-content imaging from PhenoVista Biosciences.
Neuroservices-Alliance is a leading Contract Research Organization (CRO) specializing in electrophysiological recordings from acute brain slices, cultured neurons, and in vivo models, providing the pharmaceutical industry with cutting-edge solutions for CNS drug development.
PhenoVista Biosciences excels in high-content, imaging-based assay development and screening, accelerating the discovery and development of therapeutics for myriad disease areas, including oncology, fibrosis, and CNS diseases. They offer a variety of services, from off-the-shelf, pre-determined assays to completely bespoke services.
Under this co-marketing agreement, Neuroservices-Alliance and PhenoVista Biosciences will actively collaborate to ensure that their clients receive a comprehensive suite of services tailored to their specific needs, ultimately enhancing the drug-discovery process.
“We are excited to partner with PhenoVista Biosciences. By offering functional endpoints to complement their cutting-edge imaging capabilities, we are offering our clients a broader range of complementary services and deeper insights into their CNS drug discovery programs.”
Olivier Toury, Co-founder and CBO, Neuroservices-Alliance contact:
“We are enthusiastic about embarking on a formal partnership with our friends and neighbors at Neuroservices-Alliance. Both of our companies share a commitment to the highest quality of data and a focus on customer service. We look forward to providing current and future clients with the fruits of our combined capabilities!”
James Evans, CEO and Co-founder, PhenoVista Biosciences
For more information on how this partnership can benefit your CNS drug discovery program, please contact:
